Compare CCCC & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | STXS |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.3M | 210.0M |
| IPO Year | 2020 | 2004 |
| Metric | CCCC | STXS |
|---|---|---|
| Price | $2.42 | $2.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $8.50 | $4.00 |
| AVG Volume (30 Days) | ★ 1.4M | 471.8K |
| Earning Date | 11-06-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,108,000.00 | $30,075,000.00 |
| Revenue This Year | N/A | $24.48 |
| Revenue Next Year | N/A | $29.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 19.62 |
| 52 Week Low | $1.09 | $1.54 |
| 52 Week High | $4.70 | $3.59 |
| Indicator | CCCC | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 43.19 |
| Support Level | $2.50 | $2.34 |
| Resistance Level | $2.69 | $2.44 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 10.21 | 46.55 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.